BioSpace News Archive

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the three months and year ended December 31, 2023, and provided a corporate update.

Stryker announced its 2024 Annual Meeting of Shareholders is scheduled as follows.

Diagnostic company SphingoTec announces a significant change in its management team. Joerg Menten, Managing Director and CEO, leaves the company to enter into retirement.

Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically well-established pharmaceutical products across key therapeutic areas, announces that it has signed a Distribution Agreement with AcedrA BioPharmaceuticals (“AcedrA”), a leading Saudi company operating in the Middle East and North Africa region.

Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that the company will be participating in the 23rd Annual Needham Virtual Healthcare Conference, which is being held virtually from Monday, April 8 to Thursday, April 11, 2024.

Domain Therapeutics (“Domain” or “the Company”) today announces that latest preclinical data on DT-9045, a novel protease-activated receptor 2 (PAR2) Negative Allosteric Modulator candidate, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California.

Yield10 Bioscience, Inc. reported that the Plant Biosafety Office of the Canadian Food Inspection Agency recently reviewed information on the Company’s E3902 Camelina sativa and determined that E3902 is not a Plant with Novel Trait and is not subject to a pre-market notification under Part V of the Seeds Regulations.

Telomir Pharmaceuticals, Inc. announced that Telomir and global animal health research company Argenta have agreed to begin a three to six-months study on the efficacy of Telomir-1 as a treatment for osteoarthritis and other diseases of aging in canines.

ABVC BioPharma, Inc. announced that each of the Company and its subsidiary BioFirst Corporation entered into a global licensing agreement with ForSeeCon Eye Corporation for the Company’s Ophthalmology pipeline, which includes the medical device Vitargus® .

Iveric Bio, An Astellas Company (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”), today announced the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPS) J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).